[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lumbar-discogenic-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lumbar-discogenic-pain":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100575912","clinical-trial-evaluating-the-safety-and-efficacy-of-nucleus-pulposus-allograft-in-participants-with-degenerative-disc-disease-100575912",false,"NCT06778447","Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease","Randomized, Sham-Controlled, Multi-Center, Double-Blind Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft to Supplement Nucleus Pulposus Tissue in Participants With Lumbar Discogenic Pain Associated With Degenerative Disc Disease","RESTORE","Inclusion Criteria:\n\n* Age 22 to 85 years old\n* Diagnosis of moderate to severe DDD on MRI, Modified Pfirrmann Grade 3-7\n* Chronic axial midline low-back pain in the absence of lower extremity motor\u002Fsensory\u002Freflex changes with or without referred non-radicular leg pain for at least 6 months prior to screening; unresponsive to at least 3 months of conservative care\n* Low-back pain severity score of ≥ 40 to ≤ 90 mm on the VAS\n* ODI score of ≥ 40 to ≤ 80\n* Positive sustained hip flexion test\n* Demonstrated intolerance to sitting\n* Able to give voluntary, written informed consent to participate and have signed an Informed Consent Form specific to this study\n* Willing and able to comply with all study procedures and availability for the duration of the study with a life expectancy of \\> 2 years\n\nExclusion Criteria:\n\n* Contraindications to the proposed sedation\u002Fanesthetic protocol\n* Involvement of more than two lumbar discs as evidenced by 3 or more discs with Modified Pfirrmann grade of 3 or greater\n* Disc height of less than 4mm for any disc between L1-S1\n* Symptomatic vertebral compression fracture\n* Previous surgical treatment of the lumbar spine\n* History of sacroiliac (SI) joint fusion within the past six months\n* Received lumbar epidural or intradiscal steroid injection, lumbar facet joint steroid injection, lumbar radiofrequency ablation, provocative or anesthetic discography, SI joint pain injection, injection of methylene blue, dextrose, glucosamine, and chondroitin sulfate, or biacuplasty within 3 months of the Day 0 procedure\n* Received intraosseous radiofrequency nerve ablation procedure at the same or adjacent level (e.g., Basivertebral nerve ablation or sinuvertebral nerve ablations)\n* Received prior intradiscal stem cell\u002Fprogenitor cell therapy or other biological intervention (e.g., MSC, PRP) at the target level within 12 months of the Day 0 procedure\n* Evidence of dynamic instability on lumbar flexion-extension radiographs (\\>3 mm)\n* Grade 2 or higher spondylolisthesis at the target level, lumbar spondylitis or other undifferentiated spondyloarthropathy, or Type III Modic changes adjacent to the target disc\n* Radiographic evidence of a full thickness annular tear at the target disc or other abnormal disc morphology\n* Clinical suspicion of facet pain as primary pain generator\n* A systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study (e.g. current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, recent history of myocardial infarction, uncontrolled diabetes (\\>7.0% HbA1C), etc.)\n* Received VIA Disc NP previously.\n* Deemed unsuitable for clinical study participation by the Investigator\n* Evidence of substance abuse (including marijuana); note: subjects using prescribed extended-release narcotics (e.g., fentanyl patch, MS Contin, oxycontin) within the 3 months prior to screening and subjects on long-acting opioids may be given option to wean off opiates before enrollment; subjects on short-acting opiates (e.g., hydrocodone, oxycodone, tramadol, etc.) may be included and utilization monitored after the treatment\n* Opioid use of more than 90 MME\u002Fday\n* Currently receiving treatment with radiation, chemotherapy, immunosuppression, or chronic steroid therapy (prednisone, or its equivalent, use of up to 5 mg\u002Fqd, or inhalation steroids for asthma is allowed)\n* Metal or ceramic implants in the lumbar spine region\n* Contraindications to MRI, including non-MRI compatible devices and active implantable devices such as spinal cord stimulators, intrathecal pumps, etc.\n* Involved in ongoing or closed (within 6 months of screening visit) litigation related to their back pain condition\n* Any mental instability, unstable bipolar disorders, unmanaged post-traumatic stress disorder (PTSD) or uncontrolled anxiety\u002Fdepression and\u002For require new or changed anti-depressants or anti-psychotic medications within 3 months of enrollment\n* Diagnosis of any traumatic neurological disorders that may impact the study as per the judgement of the Investigator\n* Women who are pregnant or breastfeeding at the time of enrollment and\u002For plan to become pregnant during the study; pregnancy is confirmed by:\n* a positive pregnancy test during the screening visit\n* self-reported pregnancy\n* Women of childbearing potential (WOCBP) who are not using a reliable form of contraception (as determined by the Investigator)\n* Received any experimental drug or device to treat the same condition used within 6 months prior to the screening visit or during the course of the clinical trial\n* Other persistent pain\u002Fnerve issues including, for example, radiculopathy, leg pain, cauda equine syndrome, etc.","ALL","22 Years","85 Years",{"count":21,"type":22},496,"ESTIMATED","INTERVENTIONAL",[25],"NA","VIA Disc NP is a non-surgical intervention intended to supplement nucleus pulposus tissue in degenerated intervertebral discs.\n\nThis is a randomized, sham-controlled, multi-center, double-blind clinical trial with an open label roll-in period of one participant per site in which participants with lumbar discogenic pain associated with DDD will receive one VIA Disc NP treatment to each affected level (up to 2 levels). Participants enrolled after the roll-in stage will be randomized on a 2:1 basis to receive either a single VIA Disc NP intradiscal injection at 1 or 2 levels or the sham procedure at 1 or 2 levels. At 12 months, participants in the sham arm with continued symptoms may cross-over, receive VIA Disc NP, and will restart the study visit schedule, completing an additional 12 months of follow-up post-cross-over.",[28,29,30],"Degenerative Disc Disease","Disc Degeneration","Lumbar Discogenic Pain",[28,30],"RECRUITING","2026-04-23",{"date":35,"type":36},"2026-04-24","ACTUAL",{"date":38,"type":36},"2025-02-17",{"date":40,"type":22},"2028-05",{"name":42,"class":43},"VIVEX Biologics, Inc.","INDUSTRY",19,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100370520","phase-1-the-safetyefficacy-study-of-human-umbilical-cord-mesenchymal-stem-cells-therapy-19isclife-ldp-for-lumbar-discogenic-pain-100370520","NCT04104412","The Safety\u002FEfficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-LDP) for Lumbar Discogenic Pain","The Safety\u002FEfficacy Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Lumbar Discogenic Pain","Inclusion Criteria:\n\n1. age over 18\n2. refractory and persistent lumbago pain for more than 6 months, with\u002Fwithout radiation pain in lower limbs, and poor conservative treatment effect;\n3. the straight leg elevation test was 70 degrees negative;\n4. MRI of lumbar spine showed herniated disc \\\u003C 6 mm, no obvious compression of spinal cord and nerve roots; T2-weighted mri of the lumbar spine showed decreased single\u002Fmulti-segment signal (black disc sign) or High signal zone (HIZ) in the posterior part of the intervertebral disc annulus.\n5. clinical signs of nerve localization were consistent with MRI changes;\n6. subject gives informed consent and signs informed consent.\n\nExclusion Criteria:\n\n1. coagulation dysfunction or anticoagulant therapy;\n2. intervertebral space infection, puncture site infection or systemic infection;\n3. lumbago pain of non-spinal origin, such as sacroiliac joint origin pain;\n4. patients who have had open surgery or other disc treatments;\n5. imaging examination suggested disc prolapse, prolapse, spinal canal bone stenosis, etc.;\n6. patients with vital organ system dysfunction and tumor lumbar vertebra metastasis;\n7. subjects with high tumor markers (AFP\u002FCEA\u002FCA199\u002FCA125);\n8. the subject is pregnant or breastfeeding;\n9. subjects also receive other treatments that may affect the efficacy and safety of stem cells;\n10. failing to control alcohol and other substance abuse during the 6 months prior to enrollment and enrollment period;\n11. the subjects suffer from mental illness, or lack of understanding, communication and cooperation, and cannot be guaranteed to follow the study protocol;\n\nSubjects who are not willing to sign informed consent and are participating in other clinical trials or have participated in other clinical trials within 3 months;","18 Years",{"count":54,"type":22},242,[56],"PHASE1","This experimental use umbilical cord mesenchymal stem cells in treatment of the early stage of lumbar discogenic pain (endogenous pain of the disc) to evaluate its safety and efficacy.\n\nThis experimental is mainly aimed at over 18years old people, regardless of gender, with refractory and persistent back pain for more than 6 months.\n\nThe efficacy and safety of mesenchymal stem cells (MSCS) were evaluated by low-temperature plasma ablation and intravertebral disc injection, which were divided into treatment group and control group.",[30],[60,61],"lumbar discogenic pain","mesenchymal stem cell","2026-04-22",{"date":33,"type":36},{"date":65,"type":36},"2019-08-15",{"date":67,"type":22},"2027-06-30",{"name":69,"class":43},"Sclnow Biotechnology Co., Ltd.",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":70},"100579522","auriculotherapy-neuroimaging-100579522","NCT06825390","AuriculoTherapy NeuroImaging","Mechanistic Clinical Trial of Auricular Stimulation and Cryogenic Auriculotherapy in Patients With Chronic Low-back Pain, Using Functional Near-infrared Spectroscopy and Magnetic Resonance Imaging","ATNI","Inclusion Criteria:\n\n1. Adult, at least 18 years old\n2. Episodes of chronic low back pain at least daily for at least 6 months, with an average pain score within the last week of 3\u002F10.\n\nExclusion Criteria:\n\n1. active lesions, skin disruptions, or neuropathy of either ear;\n2. recent (\\\u003C1 month) analgesic procedures or surgery;\n3. recent (\\\u003C1 month) start of new analgesic or psychoactive medication (including marijuana, opioids, tramadol, methadone, gabapentinoids, anti-depressants, anti-epileptics, mood-stabilizers, anti-psychotics, or stimulants);\n4. history of chronic pain in shoulder or thumb (to avoid confounding at control stimulation points);\n5. recent (\\\u003C 3 months) illicit drug use;\n6. prior substance misuse\u002Fabuse;\n7. cold-activated diseases (including: agammaglobulinemia, cold urticaria, cold agglutinin disease, cryofibrinogenemia, cryoglobulinemia, immunosuppression, Raynaud's disease, collagen or autoimmune diseases, multiple myeloma, platelet deficiency disorders, pyoderma gangrenosum.)\n\n   \\- MRI-specific exclusions additionally include:\n8. Pregnancy or active attempts at conception;\n9. Implanted metal or electronic device;\n10. severe claustrophobia",{"count":80,"type":22},60,[25],"This is a clinical study of patients who have low back pain (for at least 6 months). The goal is to understand, with brain imaging, how auriculotherapy (an acupuncture-like stimulation of the ear) may work to relieve pain. There are 4 total study visits, divided into two pairs of visits that occur before and 5-7 days after receiving either a real or sham auriculotherapy treatment. The cryo-IQ device will be used, to stimulate 7 small areas on both ears with a focused jet of cold as a small amount of compressed gas is released. This is generally not painful, and less invasive, compared to using needles for auriculotherapy.",[84,85,86,87,30,88,89,90,91,92],"Low Back Pain","Chronic Low-back Pain","Back Pain, Low","Lumbar Disc Disease","Lumbar Pain Syndrome","Lumbar Post-Laminectomy Syndrome","Back Pain Lower Back Chronic","Back Pain Without Radiation","Pain;Back Low;Chronic",[94,95,96,97,98,99],"auriculotherapy","auricular stimulation","functional near-infrared spectroscopy","functional magnetic resonance imaging","functional connectivity","cryo-auriculotherapy","2026-02-13",{"date":102,"type":36},"2026-02-18",{"date":104,"type":36},"2025-07-30",{"date":106,"type":22},"2029-04-30",{"name":108,"class":109},"Keith M Vogt","OTHER"]